The American Academy of Neurology 60th Annual Meeting brought news of a new Alzheimer's drug called Dimebon. The drug just made it through a pivotal phase of testing. Although it faces more trials before it will be marketable, the information implies that Dimebon could prove to be an important part of future Alzheimer's treatment.
According to the press release:
"After one year of therapy with Dimebon, Alzheimer's disease patients performed better in daily function than patients who did...
